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http://www.actaneurocomms.org/content/1/1/72RESEARCH Open AccessRapidly progressive dementia with thalamic
degeneration and peculiar cortical prion protein
immunoreactivity, but absence of proteinase K
resistant PrP: a new disease entity?
Gabor G Kovacs1*†, Alexander Peden2†, Serge Weis3, Romana Höftberger1, Anna S Berghoff1, Helen Yull2,
Thomas Ströbel1, Stefan Koppi4, Regina Katzenschlager5, Dieter Langenscheidt4, Hamid Assar6, Elisabeth Zaruba7,
Albrecht Gröner8, Till Voigtländer1, Gina Puska9, Eva Hametner10, Astrid Grams11, Armin Muigg10,
Michael Knoflach10, Lajos László9, James W Ironside2, Mark W Head2* and Herbert Budka1,12Abstract
Background: Human prion diseases are a group of rare fatal neurodegenerative conditions with well-developed
clinical and neuropathological diagnostic criteria. Recent observations have expanded the spectrum of prion
diseases beyond the classically recognized forms.
Results: In the present study we report six patients with a novel, apparently sporadic disease characterised
by thalamic degeneration and rapidly progressive dementia (duration of illness 2–12 months; age at death:
55–81 years). Light and electron microscopic immunostaining for the prion protein (PrP) revealed a peculiar
intraneuritic distribution in neocortical regions. Proteinase K resistant PrP (PrPres) was undetectable by Western
blotting in frontal cortex from the three cases with frozen tissue, even after enrichment for PrPres by centrifugation
or by phosphotungstic acid precipitation. Conformation-dependent immunoassay analysis using a range of PK
digestion conditions (and no PK digestion) produced only very limited evidence of meaningful D-N (denatured/native)
values, indicative of the presence of disease-associated PrP (PrPSc) in these cases, when the results were compared with
appropriate negative control groups.
Conclusions: Our observation expands the spectrum of conditions associated with rapidly progressive dementia and
may have implications for the understanding of the pathogenesis of prion diseases.
Keywords: Conformational assay, Prion protein, Protease-sensitive PrPSc, Prionopathy, Thalamic degenerationBackground
Human prion diseases (PrDs) are a group of rare fatal
neurodegenerative conditions with well-developed clinical
and neuropathological diagnostic criteria. The current
consensus view of their underlying pathological process
largely focuses on the presence of a pathological, disease-
associated prion protein (PrP) conformer (PrPSc) that is* Correspondence: gabor.kovacs@meduniwien.ac.at; m.w.head@ed.ac.uk
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stated.involved in neurotoxicity, infectivity and strain differenti-
ation [1]. PrPSc is distinguished from the physiological cel-
lular conformer of PrP (PrPC) by an increased β-pleated
sheet structure [2], and relative resistance to digestion with
proteinase K (PK) (the products that are resistant to PK-
digestion are termed PrPres). In human PrDs three major
PK-resistant PrP types have been described that are readily
identifiable by immunoblotting with a range of anti-PrP
antibodies: type 1 (21 kDa non-glycosylated PrPres), type 2
(19 kDa non-glycosylated PrPres), and lower molecular mass
(approximately 8 kDa) fragments [3,4]. These PrPres types
are thought to represent different conformational states of
the protein. Together with the codon 129 polymorphismLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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the molecular classification of sporadic PrDs [5].
A different approach to the detection of PrPSc is
employed in the conformation-dependent immuno-
assay (CDI). This uses increasing concentrations of
the chaotropic salt guanidine hydrochloride (GdnHCl)
to unmask epitopes in PrP that become hidden dur-
ing the formation of PrPSc. This method has provided
evidence that PrPSc also exists in abundance in protease-
sensitive forms (senPrPSc) in human PrDs [6,7]. How-
ever, CDI is not yet used routinely in human PrD
diagnosis.
According to the etiological classification of PrDs, spor-
adic (idiopathic) Creutzfeldt-Jakob disease (sCJD) is the
most frequently occurring form. This is a fatal disorder
characterised neuropathologically by widespread spongi-
form change in the brain and prominent deposition of the
disease-associated PrP with distinct morphologies [8].
However, one molecular form of sCJD differs in that only
subtle spongiform change is seen and that prominent
degeneration in the thalamus and inferior olives is the
most prominent feature [9]. Indeed, this form was termed
the thalamic form of CJD or sporadic fatal insomnia (sFI),
due to its close phenotypic and biochemical similarity to a
genetic PrD, fatal familial insomnia (FFI), which is associ-
ated with the D178N mutation in the prion protein gene
(PRNP) and methionine encoded in the mutated allele at
codon 129 [9]. Importantly, PrPres has been found (type 2)
in both sFI and FFI, and immunostaining for PrP reveals
mild, but distinct synaptic type immunodeposits [5].
Sporadic FI has always been associated with methionine
homozygosity at codon 129 (and sometimes termed “MM
type 2 thalamic CJD”) [5].
Recent observations have expanded the spectrum of
PrDs beyond the classically recognized forms associated
with abundant PrPres to include a disease called variably
protease-sensitive prionopathy (VPSPr) [10]. Immuno-
blotting shows a ladder-like pattern of protease-resistant
PrP fragments, extending from approximately 8 kDa to
the 18–30 kDa molecular mass range. Detection of the
poorly protease-resistant PrPSc in VPSPr can require
particular antibodies such as 1E4 (rather than by the 3F4
anti-PrP antibody) or enrichment after PK treatment
[10,11] for its detection by Western blotting. Nevertheless,
in VPSPr, spongiform change and the widespread pres-
ence of disease-associated PrP immunoreactivity are ob-
served, in conjunction with PrPres that is detectable by
immunoblotting. Thus, in PrDs the disease-associated
PrPSc may be in the form of PrPres or PrPsen (i.e. protease-
sensitive PrPSc or senPrPSc) but is distinguishable from the
physiological PrPC. The roles of and relationship between
senPrPSc and PrPres are not yet known, however no PrDs
have yet been described in which senPrPSc is detectable in
the apparent absence of PrPres.In the present study we report six individuals who
presented clinically with rapidly progressive dementia
and neurological symptoms. Neuropathological examin-
ation did not reveal spongiform encephalopathy, but
thalamic degeneration and a peculiar PrP immunoreac-
tivity was found in the cortex. The identification of such
cases expands the spectrum of conditions associated
with rapidly progressive dementia and may have implica-
tions for the understanding of the pathogenesis of prion
diseases.
Methods
Selection of cases
The patients were encountered and systematically investi-
gated as part of the surveillance for human PrDs in
Austria or referred to the Institute of Neurology, Medical
University Vienna, for neuropathological autopsy diagno-
sis. Samples were collected following local regulations as
part of the study (“Molecular neuropathologic investi-
gation of neurodegenerative diseases”) approved by the
Ethical Committee of the Medical University of Vienna
following the principles of the Helsinki declaration. Clin-
ical and neuroradiological data were obtained retrospect-
ively. Genetic analysis was performed using genomic DNA
isolated from blood samples or frozen brain tissue as
published previously [12]. For comparative purposes we
selected one Austrian FFI case (D178N-129MV), and two
UK cases of sporadic CJD (one of the common MM1
subtype and one of the rare MM2T or sFI subtype), which
were obtained from the UK MRC Edinburgh Brain Banks
(CJD Brain and Tissue Bank, LREC 2000/4/175, Prof J.W.
Ironside). FFI and sFI cases were selected because they
also show prominent thalamic degeneration, variable
amounts of PrP immunoreactivity and PrPres. The brain
from each of these cases used as positive controls had pre-
viously been examined histologically and biochemically,
and a definite diagnosis of sporadic CJD or sFI/FFI had
been reached by established criteria [13,14]. The protease-
resistant PrP (PrPres) isotype found in CJD brains was
classified as type 1, 2A, or 2B as previously described
according to the nomenclature of Parchi and colleagues
[3,5,15]. The polymorphic status of codon 129 of the
PRNP of each UK case was determined by restriction
fragment length polymorphism [16]. The presence of the
D178N mutation in the cases of FFI and the absence of
prion disease-associated mutations in the sFI and the
sCJD cases were determined by sequencing of the PRNP
gene ORF. Cerebral cortex samples from ten cases from
the Medical Research Council Edinburgh Brain and Tissue
bank were analysed by CDI as controls. Five of these were
sudden death cases with no history of a neurological
condition (designated ‘sudden death’), whereas another five
were cases initially referred to NCJDRSU as suspected CJD
cases, but given an alternative final diagnosis (designated
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of Alzheimer’s disease (n = 3), frontotemporal lobar degen-
eration motor neurone disease and cerebral infarction. The
VPSPr brain tissue sample used in this study was from a
patient who was VV at codon 129 of the PRNP gene and
was a generous gift from Dr. Gambetti (National Prion
Disease Pathology Reference Centre, USA).
Neuropathology
Formalin fixed, paraffin-embedded tissue blocks from
the investigated cases were evaluated including the
following anatomical regions: frontal, anterior cingulate,
parietal, temporal, occipital cortex, hippocampus, ento-
rhinal cortex, amygdala, basal ganglia, thalamus, mesen-
cephalon, pons, medulla oblongata, and cerebellum. In
addition to Haematoxylin and Eosin staining, the following
monoclonal (mouse) antibodies were used for immunohis-
tochemistry: anti-PrP 3F4 (epitope: aa. 106–112; 1:1,000,
Signet/Covance, Berkeley, CA, USA), anti-PrP L42
(epitope: aa. 141–159; 1:300, FRC for Virus Diseases of
Animals, Dr. M.H. Groschup, Tübingen, Germany) [17],
anti-PrP 12F10 (epitope: aa. 142–160; 1:1,000, Cayman
Chemical, Ann Arbor, MI, USA), anti-PrP BG4 (epitope:
aa. 23–85), anti-PrP KG9 (epitope: aa. 140–180) (both
1:1,000, TSE Resource Centre, Roslin Institute, Edinburgh,
U.K.), anti-PrP 6H4 (epitope: aa. 144–152; 1:500, Prionics,
Schlieren, Switzerland), monoclonal anti-p62 (1:1,000, BD
Transduction, Lexington KY, USA), monoclonal anti-
ubiquitin (1:50,000, Millipore, Temecula, CA, USA), anti-
tau AT8 (pS202/pT205, 1:200, Pierce Biotechnology, Rock-
ford, IL, USA), anti-phospho-TDP-43 (pS409/410, 1:2,000,
Cosmo Bio, Tokyo, Japan), anti-α-synuclein (1:2,000, clone
5G4, Roboscreen, Leipzig, Germany; specific for disease-
associated form) [18], anti-Aβ (1:50, clone 6 F/3D, Dako,
Glostrup, Denmark), and anti-amyloid precursor protein,
APP (1:500, Millipore, Billerica, MA, USA). Furthermore
polyclonal (rabbit) anti-FUS (1:1,000, SIGMA, Saint Louis,
MO, USA) and anti-GFAP (1:5,000, Dako, Glostrup,
Denmark) antibodies were also applied. The DAKO EnVi-
sion© detection kit, peroxidase/DAB, rabbit/mouse (Dako,
Glostrup, Denmark) was used for visualization of antibody
reactions. For the purpose of surveillance for PrDs in
Austria, since January 2002 we have used the antibody
12F10 for immunohistochemical analyses of brain sections.
Between January, 2002 and January, 2013 (11 years), we
have systematically evaluated 312 brains that were proc-
essed and immunostained using the same protocol de-
scribed here. In addition to 170 definitive CJD cases, 3
cases with FFI (two D178N M129M and one M129V), 2
cases with Gerstmann-Sträussler-Scheinker disease (GSS
P102L), single cases with 144 base or 120 pair insertion, a
total of 135 brains were received for examination as sus-
pect prion disease but were found to have other disorders,
and prion disease was formally excluded. This cohortcomprises diagnoses of Alzheimer’s disease, Lewy body de-
mentia, frontotemporal lobar degeneration with TDP-43
proteinopathy, corticobasal degeneration, progressive sup-
ranuclear palsy, encephalitis, vascular lesions (including the
thalamus), carcinomatous meningitis, metastases, meta-
bolic and hypoxic/ischemic encephalopathy. In addition we
evaluated 8 cases with pathology in the thalamus (six
Wernicke encephalopathy; age range: 34–73 years at death,
4 men; and two with paramedian infarct, 78 and 86 years-
old women).
In this study, neuropathological alterations (spongiform
change, astrogliosis/neuronal loss, degree of various pro-
tein depositions) were semi-quantitatively (none, mild,
moderate, severe) evaluated in different anatomical re-
gions. For PrP immunohistochemistry we compared three
pre-treatment protocols: sections were treated (1) in auto-
clave (121°C in distilled water) followed by 5 minutes in
98% formic acid, (2) by additional treatment with PK
(10 μg/ml, Dako PK Ready-to-use, Code S3020), or (3)
only 20 minutes citrate buffer (pH 6) pre-treatment in a
steamer (95°C).
Paraffin-embedded tissue (PET) blotting
This was performed with slight modifications according
to published protocols [19]. Briefly, sections of formalin
fixed, paraffin embedded brain tissue were placed onto a
nitrocellulose membrane. Sections were treated with
250 μg/ml PK or with 150 μg/ml thermolysin (both
Sigma-Aldrich) for eight hours at 56°C. Thermolysin was
used because it has been shown to degrade PrPC while
preserving both PK-sensitive and PK-resistant isoforms
of disease-associated PrP [20]. After washing, we treated
the membranes with 3 M guanidine isothiocyanate for
10 minutes. For immunodetection we used the antibody
3F4 (1:500).
Immunogold electron microscopy
After incubation of the deparaffinised tissue sections with
anti-PrP (12F10) antibody, we applied ultrasmall gold
conjugated secondary antibody (Aurion, Wageningen, The
Netherlands) followed by silver-enhancing method. Slides
were mounted with resin and examined by light micros-
copy. Selected areas containing immunoreactive structures
were re-embedded for ultrathin sectioning [21]. We used
a JEOL-1011 electron microscope to analyse the ultra-
structural localization of PrP-specific immunolabeling in
the ultrathin sections.
Immunoblotting
Analysis of brain samples by Western blotting, including
centrifugal concentration
For Western blot analysis, samples were homogenized in
nine volumes (weight to volume, w/v) of tris-buffered
saline, pH 7.6, containing 0.5% Nonidet P40 and 0.5%
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homogenates were subjected to limited proteolysis by
digestion with PK at 50 μg/ml for one hour at 37°C. The
reaction was terminated by addition of Pefabloc SC
(Roche, Burgess Hill, UK) to a final concentration of
1 mM. PK-treated samples were either analysed by Western
blotting directly, or alternatively 100 or 200 μl samples were
centrifuged at 20,800 g for one hour at 4°C and the pellets
were analysed. Polyacrylamide gel electrophoresis and
Western blotting was performed using the NuPAGE Novex
gel system (Invitrogen, Paisley, UK) as described previously
[22]. The immunodetection of PrP was achieved using the
monoclonal antibodies 3F4 (Millipore, Watford, UK), 1E4
and 94B4 (both provided by Dr Jan Langeveld [Central
Veterinary Institute of Wageningen UR, Lelystad, The
Netherlands]). The antibodies were used at final concen-
trations of 75 ng/ml, 1 μg/ml and 500 ng/ml respectively
for one hour.
Analysis of brain samples by Western blotting after sodium
phosphotungstic acid precipitation
Sodium phosphotungstic acid (NaPTA) precipitation
was performed as published previously [23,24], with a
few minor modifications. Briefly, 0.5 ml samples of 10%
(wt/vol) cleared brain homogenates prepared for CDI
analysis in 2% sarkosyl/PBS (see below) were diluted
with a further 0.5 ml of 2% sarkosyl/PBS and incubated
for 10 minutes at 37°C. Benzonase (Sigma E1014) and
MgCl2 were added at final concentrations of 50 U/ml
and 1 mM, respectively, and incubation at 37°C was con-
tinued for a further 30 minutes. 81 μl of a stock solution
of 4% (wt/vol) NaPTA and 34 mM MgCl2, pH 7.4, was
added (final concentration of NaPTA, 0.3% [wt/vol]),
and precipitation was allowed to occur for 30 minutes
at 37°C. The samples were centrifuged at 20,800 g for
30 minutes at 37°C. The pellets were resuspended in
20 μl of 0.1% (wt/vol) sarkosyl in PBS, pH 7.4, and
digested with 50 μg/ml PK for 30 minutes at 37°C. Diges-
tion was terminated by the addition of 1 mM Pefabloc SC
(Roche, Burgess Hill, UK). Electrophoresis and transfer
was performed as described above but the detection
reagent used was SuperSignal West Femto maximum
sensitivity substrate (Pierce, Rockford, IL, USA). Images
were again obtained using the ChemiDoc™ XRS system
and Image Lab software (Bio-Rad).
Conformation-dependent immunoassay (CDI)
Homogenization of brain samples for CDI analysis
Frozen tissue samples were weighed and homogenised in
phosphate buffered saline (P5493, Sigma-Aldrich, Dorset,
UK) containing 2% sarkosyl (N-laurylsarcosinate 61745,
Sigma-Aldrich) using a buffer volume that gave a final
tissue concentration of 10% (wt/vol). The homogenization
was performed in tubes containing lysing matrix D usingthe Fast-Prep instrument (MP Biomedicals, Solon, Ohio,
USA). Three 45-second rounds of lysis were performed at
6.5 ms-1 separated by five-minute intervals to allow
cooling. The homogenates were then cleared of cellular
debris by centrifugation at 5200 g for five minutes at 4°C.
The supernatants were transferred to fresh tubes and
stored at −80°C.
Analysis of brain homogenates by CDI
Brain homogenates were either assayed by CDI directly,
or following limited proteolytic digestion with 2.5 or
50 μg/ml PK for one hour at 37°C. PK digestion was ter-
minated by the addition of 1 mM Pefabloc SC. The CDI
method used in this study was performed as described
previously [7,25] (but omitting the NaPTA precipitation
step). In CDI PrPSc is detected on the basis of an in-
crease in signal following sample denaturation as epi-
topes hidden within misfolded PrPSc become exposed. In
CDI, PrP is detected using the dissociation enhanced
lanthanide fluorescence immunoassay (DELFIA) tech-
nology of PerkinElmer (PerkinElmer, Cambridge, UK).
Samples of brain homogenates prepared as described
above were divided into two equal aliquots. One aliquot
was mixed with an equal volume of 8 M guanidine hy-
drochloride (GdnHCl) and denatured (D) by incubating at
81°C for six minutes and the other was diluted without
GdnHCl and left at room temperature and designated na-
tive (N). Both D and N samples were adjusted to a final
volume of 650 μl and a final guanidine concentration of
308 mM, with water containing complete™ EDTA-free
protease inhibitors (Roche). A 96-well black polysty-
rene plate (Fisher, Loughborough, UK) was coated with
2.5 μg/ml (0.5 μg/well) anti-PrP capture antibody MAR-1
(CSL Behring, Marburg, Germany) diluted in carbonate-
bicarbonate buffer overnight at room temperature. The
wells were washed four times with DELFIA wash buffer
(PerkinElmer) using a Model 1575 Immunowash micro-
plate washer (Bio-Rad). After saturating the plate by sha-
king for one hour with 0.5% (wt/vol) bovine serum albumin
and 6% D-sorbitol (wt/vol) in DELFIA wash buffer, the
wells were washed four times and the D or N samples were
loaded in triplicate onto the plate (200 μl/well).
The samples were incubated on the plate for two
hours at room temperature with shaking. The plate was
washed four times and europium-conjugated PrP antibody
3F4 (~25 ng/ml) in DELFIA assay buffer (200 μl/well) was
added to all wells and incubated for two hours at
room temperature with shaking. The wells were then
washed six times and DELFIA enhancement solution
(200 μl/well) was added to all wells. After incubation
for five minutes at room temperature with shaking,
the time-resolved fluorescence signals for the denatu-
red and native samples were measured using a Victor 2
fluorometer (PerkinElmer).
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The CDI assay for PrP was calibrated using full-length
human recombinant PrP (recHuPrP, amino acids 23–
231, methionine at codon 129) purified as described
previously [26]. A range of dilutions from 40 μg/ml to
10 μg/ml of this recHuPrP was prepared using PBS
containing 2% sarkosyl. Twenty-five μl samples of these
dilutions were mixed with an equal volume of 8 M
GdnHCl and denatured as described above. These sam-
ples were adjusted to 650 μl, with water containing
complete™ EDTA-free protease inhibitors and analysed
as described above. The time resolved fluorescence
counts obtained for the reHuPrP dilution series were
used to plot a standard curve of counts versus micro-
grams of PrP. This curve was used to convert the CDI
signals obtained for known volumes of 10% (wt/vol)
brain homogenates into values with units of micrograms
of PrP per gram of brain tissue. The mean values
obtained for the N and D samples are assumed to corres-
pond to PrPC and total PrP (PrPC + PrPSc) respectively.
The mean D-N value for each sample tested was used as
an estimate of PrPSc.
Results
Case reports
Case 1
A 77-year-old woman presented with progressive cogni-
tive decline associated with psychiatric symptoms. Later
gait ataxia appeared and myoclonus was observed in the
extremities. Pyramidal signs were observed terminally.
Examination of CSF 14-3-3 revealed strong positivity,
with a normal cell count and moderately elevated pro-
tein (64 mg/dl), while the EEG did not show periodic
sharp waves or triphasic components. MRI was not per-
formed. She died after a 12-month illness in April 2010.
Clinically sCJD was suspected. No mutations were found
in the PRNP gene; the codon 129 was MM.
Case 2
A 55-year-old woman presented with progressive de-
mentia and a gait disorder associated with choreiform
movements developing within a few months. She recei-
ved tiapridhydrochloride and haloperidol. Screening for
Huntingtin mutations excluded any alteration. In January
2011 she was admitted to hospital due to impairment in
gait and the appearance of myoclonus. An akinetic-rigid
state was observed and she was unable to walk. Cranial
CT revealed widening of the sulci in the frontotemporal
areas and moderate ventricle enlargement. Routine
laboratory parameters were in a normal range. After
admission, a generalized epileptic seizure occurred, and
levetiracetam therapy was initiated with discontinuation
of the neuroleptic drugs. Only mild chorea was noted at
this time. EEG revealed theta-delta waves with focalspikes in the temporal region bilaterally. Mini Mental
State was 10/30. Soon dysphagia appeared with recur-
rent aspiration pneumonia. After a temporary stay at
home, she was re-admitted in late April 2011. Pyramidal
signs and akinetic mutism were observed and she died
due to respiratory insufficiency after 12 months of
illness. CJD was suspected only terminally, and CSF 14-
3-3 and MRI were not conducted. No mutations were
found in the PRNP gene; the codon 129 was MM.
Case 3
This 81-year-old man presented with visual hallucina-
tions, which rapidly progressed to cortical blindness. In
addition ataxic gait and progressive cognitive decline
were documented. Later myoclonus was observed in the
extremities. Examination of CSF 14-3-3 revealed moder-
ate positivity, with a normal cell count, while the EEG
did not show periodic sharp waves or triphasic compo-
nents. Cranial MRI did not reveal signal alterations in
the thalamus, basal ganglia or cortex (Additional file 1:
Figure S1a). He died after a 2-month illness in April
2013. Clinically sCJD was suspected. No mutations were
found in the PRNP gene; the codon 129 was MM.
Case 4
This 74-year-old woman with a 6-month history of ataxia
and cognitive decline was admitted to a Neurology
Department. Her father had died at the age of 63, and her
mother at the age of 73 years, both with pulmonary
disease, but without a neuropsychiatric disorder. Neuro-
logical examination revealed mild rigidity of the neck
muscles and mild gaze impairment in all directions, while
myokymia was observed in the temporal and masseter
muscles. In addition hypacusis, hypomimia, myoclonus in
the shoulder muscles, dysphagia, limb (right > left) and
axial rigidity, ataxia, dysdiadochokinesia, slow psycho-
motor activity, acalculia, apraxia, and urinary incontinence
were also described. Mini Mental State was 20/30, which
decreased to 7/30 after a week. Repeated cranial MRI
revealed ventricular enlargement with periventricular
white matter T2 hyperintensities and moderate diffuse
cortical atrophy (Additional file 1: Figure S1b). In addition,
a tumor (neuroradiologically compatible with acoustic
schwannoma) was observed in the left cerebellopontine
angle (27x16x19 mm); this did not show progression. In-
creased pressure of CSF was not detected, and no clinical
improvement was observed after taking 30 ml CSF. At this
time urinary incontinence was not present. Examination
of the CSF showed normal cell count. Protein 14-3-3 was
moderately positive. Dopamine transporter (DAT)-SPECT
showed loss of DAT density in the basal ganglia (left pre-
dominant) and was suggestive of Parkinson’s disease.
However L-Dopa substitution did not lead to improve-
ment. EEG was performed on days 4, 19, 31 and 62 after
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waves in the frontotemporal regions bilaterally (Additional
file 1: Figure S1c). Soon after akinetic mutism developed
and the patient died due to aspiration pneumonia after
6 months duration of illness in April 2011. Clinically sCJD
was suspected. No mutations were found in the PRNP
gene; the codon 129 was heterozygous (MV).
Case 5
This 62-year-old man was admitted to the Neurology
department in July 2010, due to progressive gait disorder
in the past 6 months. There was neither a history of
neuropsychiatric disease in his parents nor a relevant
personal medical history, except for alcohol abuse.
Neurological examination revealed hypomimia, mild dys-
arthia, bradykinesia, limb ataxia (left > right) and distal
hypesthesia in the lower limbs. Barthel index was 90/100,
Mini Mental State 24/30, clock test 3/7. Cranial MRI
showed diffuse cortical atrophy and DAT SPECT revealed
bilateral decreased striatal expression. A neurodegenera-
tive Parkinsonian syndrome, cognitive decline, alcohol
abuse with hepatopathy (elevated plasma ASAT/GOT)
and polyneuropathy were diagnosed; L-Dopa, low-dose
dopamine-agonist, gabapentin, rasagilin, and dexibuprofen
therapy was initiated. He was re-admitted to the hospital
in January 2011 due to non-compliance with the therapy,
depressive mood, visual hallucinations, agitation and on-
going alcohol abuse. CSF protein 14-3-3 was not assessed.
He died due to pneumonia within 2 weeks. The duration
of illness was 9 months. Dementia with Lewy bodies
(DLB) was suspected clinically although it was felt that the
patient’s long-standing alcohol abuse precluded a clinical
diagnosis of probable DLB. Analysis of the PRNP gene
was not performed.
Case 6
In March 2012 a 79-year-old woman with a 6-month his-
tory of progressive gait disorder, cognitive decline and most
recently, change of character and oculomotor disturbance,
was transferred to the clinic for further evaluation. The
neurologic exam showed hypersomnolent apathy, amnesic
syndrome, and impaired gaze. Cerebral MRI revealed bi-
thalamic signal-alterations in FLAIR and diffusion-weighted
sequences (Additional file 1: Figure S1d,e). EEG showed
continuous generalized delta-theta activity but no periodic
or triphasic waves. Extended CSF examination showed no
signs of encephalitis or paraneoplastic disease. Due to the
clinical presentation as well as matching imaging and
laboratory findings with marked generalized vitamin and
protein deficiency and a history of severe chronic gastritis,
non-alcoholic Wernicke encephalopathy was initially sus-
pected. Despite vitamin and protein replacement therapy
the patient’s clinical status deteriorated and the patient
died one month after admission because of respiratoryinsufficiency due to pleural effusion. Considering course
and progression of disease, sCJD was suspected terminally.
Analysis of the PRNP gene was not performed.
Summary of clinical data
The age range of the patients was between 55 to 81 years
at death and the duration of illness varied between 2 and
12 months (Table 1). The major clinical features were pro-
gressive dementia and gait disorder, ataxia, myoclonus,
and extrapyramidal symptoms, including Parkinsonism in
three, supported by decreased striatal DAT expression in
two. Neither prominent sleep disorder nor polysomno-
graphy were reported or performed. EEG did not reveal
periodic sharp wave complexes or permanent triphasic
waves; CSF 14-3-3 was examined in three and showed
positivity in all. Cranial MRI was performed in four;
increased signal in the thalamus was observed in one. In
five cases CJD was suspected clinically (in two only
terminally) and in three could be classified as probable
according to the WHO Surveillance criteria [27] prior to
autopsy. Neither neurosurgery nor ophthalmic surgery
had been performed; they had not received growth or
gonadotropin hormone therapy. A positive family history
for neuropsychiatric disorders was not reported in any of
the cases.
Neuropathological, immunohistochemical, and
ultrastructural observations
Macroscopical evaluation of the brains revealed atrophy of
the thalamus and additionally mild to moderate cerebral
cortical atrophy in all lobes in case 1, 3 and 6, moderate
atrophy in the caudate nucleus with mild depigmentation
of the substantia nigra in cases 2 and 5, and a mild degree
of atrophy in the frontal and temporal lobes in cases 4 and
5. There was a lack of macroscopic evidence of discolor-
ation of the mammillary bodies or petechial haemorrhages
in the medial thalamus or brainstem tegmentum.
Common histopathological features
All six cases showed a relatively uniform histopatho-
logical phenotype (Table 2) characterised by prominent
neuronal loss and reactive astrogliosis in the thalamus.
In particular, the medial (Figure 1a,b), but also median
and intralaminar nuclei were affected, while the anterior
nucleus was only moderately affected, and lateral thal-
amic nuclei were not involved. In addition segmental
gliosis of the inferior olives together with occasional
vacuolated neurons (Figure 1c), and mild to moderate loss
of neurons in the substantia nigra was noted. There was a
lack or only subtle presence of classical spongiform
change as described in CJD. However, a moderate degree
of spongiosis of the superficial layers in the frontal, tem-
poral, and parietal cortex as seen also in other neurode-
generative diseases (i.e. Alzheimer’s, dementia with Lewy
Table 1 Overview of clinical data and performed examinations in the six patients
Patient Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Age at death 77 55 81 74 62 80
Duration of illness 12 12 2 7 9 7
Sex F F M F M F
Codon 129 MM MM MM MV NA NA
Symptoms
Progressive dementia + + + + + +
Ataxia (Gait or Limb) + + + + + +
Parkinsonism - + - + + -
Myoclonus + + + + - -
Chorea - + - - - -
Pyramidal signs + + - - - -
Oculomotor disturbance - - - - - +
Cortical blindness - - + - - -
Clinical suspicion CJD CJD CJD CJD DLB + ALC WE/CJD
WHO Criteria (CJD) Prob Poss Prob Prob * -
Examinations
CSF 14-3-3 + NA + + NA NA
MRI No No Yes Yes Yes Yes
CDI (PM) Yes Yes NA Yes NA NA
WB (PM) Yes Yes NA Yes NA NA
Neuropathology
BB stage 2 2 2 0 0 2
Thal Phase No 1 1 No No 1
Lewy body (B Stage) No No No No No No
phTDP-43 No No No No No CA1 syn
Other No No AG, MH No No No
*Retrospectively could be evaluated as “possible CJD”. Abbreviations: F female, M male, CJD Creutzfeldt-Jakob disease, DLB dementia with Lewy bodies, ALC alcoholic
encephalopathy, WE Wernicke encephalopathy, AG argyrophilic grains, MH microhaemorrhages in the hypothalamus, NA not available, CA1-syn synaptic deposits in
hippocampus CA1. Thal phase indicates the phases (1–5) of the deposition of beta-amyloid in the brain [28]. BB indicates Braak and Braak stages of neurofibrillary
degeneration [29].
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Gliosis was moderate in the striatum, while neocortical
areas were variably involved, in particular the second and
third layers (Figure 1d).
Immunostaining for PrP revealed a characteristic pat-
tern in the neocortical regions. Tiny granular deposits
apparently decorating branching neuronal processes in a
linear or worm-like appearance with tiny varicosities
were observed predominantly in the second and third
layers (Figure 2a-c). In cases 2 and 3 we observed similar
immunoreactivity in the molecular layer of the cerebel-
lum parallel to the surface (Figure 2c inset). Occasion-
ally, small cell bodies were depicted as well (Figure 2d).
Plaque-like or intraneuronal inclusion-like deposits [21]
were not seen. Neuritic deposits were best detected by
12F10, 6H4, L42, and KG9, only focally by 3F4, and not
by the anti-N-terminal BG4 antibody (Figure 2e-h).Significantly, PK treatment completely abolished this
staining (Figure 2i, j), while it was slightly more detectable
when using only elongated citrate buffer pre-treatment
and omitting formic acid pre-treatment (Figure 2k, l).
Interestingly, PET-blot examination performed using Ther-
molysin digested PrPC completely from the frontal cortex
brain tissue of a non-CJD control case, while in the present
cases the worm-like structures remained visible, and in the
cortex of a subject with CJD abundant PrPSc deposition
was seen (Figure 1m-o). PET-blot performed with PK was
negative in a non-CJD control case and the present
cases, but positive in a case of sFI and sCJD (Additional
file 1: Figure S2). Ultrastructural examination of the
same immunoreactivities in the same section (case 1)
demonstrated intraneuritic localization of immuno-gold
particles, partly associated with endosomal structures
(Figure 3). A similar morphological appearance of PrP
Table 2 Summary of neuropathological observations
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Region SC G PrP SC G PrP SC G PrP SC G PrP SC G PrP SC G PrP
Frontal Cx + ++ ++ + + + - - + - + + - ++ - + ++ +
Parietal Cx - + - + + ++ - + + - + ++ - ++ ++ + ++ +
Temporal Cx - + + - + - - - - - + + - - - - - -
Occipital Cx - + + - ++ +++ - + +++ - + + - ++ ++ NA NA NA
Entorhinal Cx + - - - - - - - - - - - - - - - - -
Hippocampus - - - - - - - - - - - - - - - - - -
Thalamus-Med - +++ - - +++ - - +++ - - +++ - - +++ - - +++ -
Thalamus-Lat - + - - ++ - - - - - - - - - - - - -
Thalamus-Ant - ++ - - + - - + - - + - - ++ - - ++ -
Caudate nucleus - ++ - - ++ - - + - - ++ - - ++ + - + -
Putamen - + - - ++ - - - - - + - - + - - + -
Globus pallidus - - - - - - - - - - - - - - - - - -
Substantia nigra - + - - - - - - - - + - - + + - + -
Dorsal raphe nucleus - + - - + - - + - - ++ - - + - - - -
Locus coeruleus - - - - - - - - - - - - - - - - - -
Pontine base nuclei - - - - - - - - - - - - - - - - - -
Inferior olive - ++ - - ++ - - + - - ++ - + +++ - ++ ++ -
Dentate nucleus - - - - - - - - - - - - - - - - + -
Cbll Mol layer - - - - - + - - + - - - - - - - - -
Cbll Gran Layer - - - - - - - - - - - - - - - - - -
Purkinje cells - - - - ++ - - - - - - - - - - - - -
SC spongiform change; G gliosis; PrP immunoreactivity for PrP; NA not available; Cx cortex; Med medial; Lat lateral; Ant anterior; Cbll cerebellum. Semiquantitative
scoring: – indicates none, +: mild, ++: moderate, +++: severe degree of changes or amount of immunoreactivity.
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ite CJD cases without selective thalamic degeneration,
GSS, base pair insertion cases, or in the cases with
other neuropathological diagnoses (see above). Accord-
ingly, we defined this branching or linear neuritic im-
munoreactivity for senPrPSc as a specific feature for the
six cases with thalamic degeneration. In none of the
cases with Wernicke encephalopathy we observed simi-
lar PrP immunoreactivity. However, in two FFI cases
with MM at codon 129 we observed similar deposits in
the frontal and occipital cortex, while in the FFI case
with MV at codon 129 this was very occasional and
associated with synaptic deposits characteristic of PrDs
(Additional file 1: Figure S3). Immunostaining for alpha-
synuclein, phospho-TDP-43 and FUS did not reveal any
pathological deposits, while anti-phospho-tau showed oc-
casional tiny neuritic profiles in the neocortex. There was
a lack of ischaemic/hypoxic damage in the cortical areas
showing the peculiar PrP immunoreactivity; moreover,
anti-APP did not demonstrate bulbs or axonal staining.
Additional alterations detected in some cases
Segmental loss of Purkinje cells was observed in case 2.
A mild degree of neurofibrillary degeneration was notedin four cases (Braak & Braak stage II; Table 1). Scattered
neurons with cytoplasmic p62 immunoreactive granular
bodies were seen in the thalamus, and in cortical areas
where PrP immunoreactivity was seen only in Patient 2,
while other regions and brains of further subjects did
not exhibit p62 inclusions. Case 6 (80 years-old) showed
synaptic and thin neuritic phTDP-43 immunoreactive de-
posits in the CA1 subregion of the hippocampus. In case
3 tiny microhemorrhages in the hypothalamus/corpus
mamillare reminiscent of Wernicke encephalopathy were
observed, however, without obvious capillary proliferation.
Periaqueductal regions of the brainstem did not show hae-
morrhages, and there was a lack of Prussian-blue positive
blood pigments. The gliotic medial thalamus nuclei did
not show haemorrhages or endothelial proliferation.
Biochemical investigation
Frozen specimens of frontal cortex, occipital cortex and
cerebellum from case 1, frontal cortex from case 2, and
frontal cortex and cerebellum from case 4 were initially
available for study and were used for the detection of PrPres
by Western blotting. A routine diagnostic Western blotting
method involving digestion of a 10% w/v brain homo-
genate with 50 μg/ml proteinase K (PK), electrophoresis of
Figure 1 Neuropathological observations. Prominent neuronal loss and gliosis in the medial thalamus. (a: H&E, b: GFAP; representative image
of case 1) associated with segmental gliosis and vacuolation in the inferior olives (c; representative image of case 5; inset demonstrates
vacuolated neuron). Moderate gliosis mainly in the upper layers of the cortex (d; representative image of case 4). Bar in a indicates 50 μm for a,
30 μm for b, 100 μm for c, and 150 μm for d.
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3F4 anti-PrP antibody (epitope: residues 106–112 of the
human PrP sequence) consistently failed to detect PrPres in
these samples (data not shown).
Enrichment for PrPres that might have been present at
low abundance in these specimens was attempted using
two different methods. First, centrifugation of PK treated
brain homogenate, and second, sodium phosphotungstic
acid (NaPTA) precipitation of abnormal prion protein
and subsequent PK digestion, both enrichment methods
followed by Western blot analysis using the 3F4 anti-
body. The centrifugal enrichment method used a start-
ing volume of 200 μl but failed to detect PrPres in the
18–30 kDa molecular mass region that is characteristic
of CJD (Figure 4a). Similar analysis of 100 μl brain hom-
ogenate samples from a variety of regions from a case of
FFI shows that the centrifugal enrichment method is
sufficiently sensitive to detect PrPres in this form of PrD,
which is known to be characterised by relatively low
levels of PrPres, compared to CJD (Figure 4b). NaPTA
precipitation allows for the analysis of larger volumes of
brain homogenate (500 μl). However, when frontal cor-
tex, occipital cortex and cerebellum from case 1, frontal
cortex from case 2, and frontal cortex and cerebellum
from case 4 were analysed by this method, the only
signal seen was a faint, poorly resolved band at around30 kDa (Figure 4c). The possible significance of such
faint bands was investigated by comparing one of these
samples (frontal cortex from case 2) with similarly pre-
pared and analysed samples from five non-CJD cases.
The analysis failed to show any bands specific to the
sample from case 2 (Additional file 1: Figure S4).
The recently described prion disease VPSPr is charac-
terised by poorly protease resistant prion protein that is
detected in the form of a low abundance 8 kDa PrPres
fragment accompanied by a faint ladder of bands
extending into the 18–30 kDa region. Comparison of
samples of occipital cortex from case 1 and frontal and
occipital cortex from case 2 with a frontal cortex sample
from a known case of VPSPr using centrifugal enrich-
ment from 50 μl of a 10% w/v brain homogenate failed
to provide any evidence of an 8 kDa band characteristic
of VPSPr in case 1 or case 2 (Figure 5a). Prolonged ex-
posure of the same blot, which included direct loading
of 20, 10 and 5 μl of the 10% w/v VPSPr brain homogen-
ate, indicated that if the 8 kDa band is present it must
be at a level ten times less than in the VPSPr sample
(Figure 5b). Prolonged exposure of these blots did
however result in the presence of some very faint bands
in the 8–30 kDa region. The possible significance of
such faint bands was investigated by comparing one of
the samples (frontal cortex from case 2) with similarly
Figure 2 Immunostaining for PrP. Immunostaining for PrP revealed tiny granular deposits depicting neuronal processes in a linear or worm-like
appearance predominantly in the 2nd and 3rd layers in neocortical regions. (a-c; representative images of case 2; right upper inset in c shows
similar immunoreactivity in the cerebellum in case 3). Occasionally, small cell bodies were depicted as well (d). These were detectable also by
antibodies 6H4 (e), and KG9 (f), only focally by 3F4 (g), and not by the anti-N-terminal BG4 antibody (h all representative images of case 4). The
PrP immunoreactivity (i) was abolished after PK treatment (j; temporal cortex of case 1), while it was slightly more detectable when using only
elongated citrate buffer pretreatment and omitting formic acid pretreatment (k: with, and l: without formic acid, represented by the occipital
cortex of case 5). PET-blot examination performed using Thermolysin digested PrPC completely from the frontal cortex brain tissue of a non-CJD
control case (m), while in the present cases the worm-like structures (enlarged in right upper inset) remained visible (n), and in the cortex of a
subject with CJD abundant PrPSc deposition was seen (o). Bar in a represents 150 μm for a, 50 μm for b, e-l, 30 μm for c, 10 μm for d, and
400 μm for m-o.
Kovacs et al. Acta Neuropathologica Communications 2013, 1:72 Page 10 of 19
http://www.actaneurocomms.org/content/1/1/72prepared and analysed samples from five non-CJD cases.
The analysis failed to show any bands specific to the
sample from case 2 (Additional file 1: Figure S5).
The 1E4 anti-PrP antibody (epitope residues 98–103
of the human PrP sequence) has been reported to have a
high sensitivity for PrPres detection in Western blotting
of VPSPr brain. However, the use of this antibody failed
to detect any additional bands in Western blot analysis
of 24 μl of 10% w/v frontal cortex homogenate from case
2 (Figure 6a) as compared with use of the 3F4 antibody
on a duplicate blot (Figure 6b). The possibility of exten-
sive N-terminal truncation of PrPres and consequent loss
of the 3F4 and 1E4 epitopes was tested by screening afurther replicate Western blot with the monoclonal anti-
body 94B4 (epitope residues 187–194 of the human PrP
sequence). However, this approach failed to provide
evidence of C-terminal PrPres fragments in the frontal
cortex homogenate from case 2 (Figure 6c).
Conformation dependent immunoassay (CDI) using a
capture antibody to a discontinuous C-terminal epitope
(MAR-1) and detection using a Europium conjugated
detection antibody (3F4) that recognises its epitope in
denatured, but not native PrPSc was then used as an
alternative sensitive PrPSc detection method that does
not necessarily depend on the presence of protease-
resistant abnormal PrP. The time resolved fluorescence
Figure 3 Ultrastructural localisation of PrP using antibody 12F10 in the same frontal cortex section where light microscopical
immunohistochemistry revealed linear and worm-like immunoreactivity. Panel a-d demonstrates immunogold labeling specific for PrP
mainly associated with endosome-like structures in the pericaryon (indicated by arrows; Nu: nucleus). Intraneuritic accumulation of PrP in
longitudinal (e) and cross (f) sections of myelinated axons. Measuring bars represent 2 μm in a, c, d, and e, and 500 nm in b and f.
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binant human prion PrP and the results expressed as μg
PrP/g of brain sample analysed. The values obtained
under native conditions were taken to be a measure of
normal cellular prion protein (PrPC), whereas any in-
crease in values obtained following denaturation with
guanidine hydrochloride (D-N) were taken to indicate
the presence of PrPSc.
CDI analysis of frontal cortex specimens from cases 1,
2 and 4 all showed high native (N) CDI values indicative
of abundant PrPC and in one sample from case 1 and
two samples from case 2 positive denatured minus
native values (D-N) were seen, indicative of the presence
of PrPSc (Figure 7a). Positive D-N values were seen in
frontal cortex samples from sCJD cases of the MM1 and
“thalamic variant” (MM2T) or sFI subtypes and from a
case of FFI (Figure 7a). Treatment of brain samples with
a low level of PK (2.5 μg/ml) prior to CDI analysis effect-
ively abolished the N values in all samples indicating the
removal of PrPC. D-N values for the samples from cases
1, 2, and 4 were markedly reduced by mild PK treat-
ment, whereas a considerable D-N value remained aftertreatment of sCJD and FFI samples with PK at this level
(Figure 7b). A proportion of this D-N signal in the cases
of CJD and FFI resisted digestion with higher levels of
PK (50 μg/ml), whereas the D-N values from the
samples of cases 1, 2 and 4 became very low indeed
(Figure 7c).
It remained possible that brain regions other than
frontal cortex might contain more readily CDI-detectable
PrPSc in cases 1, 2 and 4. Samples of additional brain
regions were obtained for case 2 and these were analysed
by CDI without prior PK treatment or with mild PK treat-
ment (2.5 μg/ml). In no brain region of case 2 (including
the thalamus) did the D-N value exceed that found in the
frontal cortex when CDI was performed in the absence of
PK treatment (Additional file 1: Figure S6a). Following
low-level PK treatment, the D-N values of all regional
samples were again markedly reduced (Additional file 1:
Figure S6b).
In order to establish whether the low D-N values
determined for frontal cortex of case 2 (Figure 7a) were
meaningful and represented the detection of PrPSc, we
conducted CDI analysis using frontal cortex samples
Figure 4 Western blot analysis of present cases 1, 2, and 4 and
an Austrian FFI case using 3F4 as the primary antibody. PrPres
type 1, 2A and 2B standards were run in the lanes as indicated.
a: PrPres was undetectable in 200 μl (of 10% wt/vol brain homogenate)
after centrifugal concentration. b: Centrifugal concentration (100 μl of
10% wt/vol brain homogenate) shows readily detectable PrPres in the
A-FFI case. c: PrPres was undetectable in 500 μl of 10% wt/vol brain
homogenate from cases 1, 2 and 4 after NaPTA precipitation. FC,
frontal cortex; OC, occipital cortex; CB, cerebellum; TC, temporal cortex;
H, hippocampus; Thal, thalamus.
Figure 5 Western blot analysis of PrPres in frontal cortex (FC) or
occipital cortex (OC) of cases 1 and 2 compared to cortical
samples of a variably protease sensitive prionopathy (VPSPr)
case and a sporadic Creutzfeldt-Jakob disease of the VV2
subtype (sCJD (VV2)). Sample loadings (μl of a 10% w/v brain
homogenate) are shown for all lanes. Sample loading in square
brackets ([]) denote volumes concentrated prior to loading. The
positions molecular mass of marker proteins (Markers) and the low
molecular mass PrPres characteristic of VPSPr are given in kilodaltons
(kDa). (a) and (b) show short (3 minutes) and long (30 minutes)
exposures of the same Western blot.
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non-CJD cases and five cases of sudden death were
analysed and used to establish cut off values (mean plus
2.5 times the standard deviation). Whether examined as
a group (Figure 8a) or considered as individual samples
(Figure 8b) the D-N values of frontal cortex samples
from cases 1 and 2 were at best only borderline positive
with respect to these cut-off values. The introduction of
low level PK treatment prior to CDI analysis fails to pro-
vide any better distinction between the D-N values from
frontal cortex from case 2 and the two negative control
groups. In each group the D-N values fell abruptly
between treatment with 1 μg/ml and 2.5 μg/ml PK
(Figure 8c).
In summary, Western blotting using a range of rele-
vant anti-PrP antibodies (to detect different PrPres frag-
ments) and two different sample enrichment methods
(to increase PrPres detection sensitivity) failed to produceevidence of PrPres in these cases, similar to that which is
found in CJD, sFI, FFI or VPSPr (Figures 4, 5 and 6).
CDI analysis using a range of PK digestion conditions
(and no PK digestion) produced only very limited
evidence of meaningful D-N values, indicative of the
presence of PrPSc in these cases, when the results were
compared with appropriate negative control groups
(Figures 7 and 8).
Discussion
General context
Distinct neurodegenerative diseases are characterised by
progressive loss of neurons predominantly from specific
anatomical regions, and this presumably accounts for
the specific focal deficits and clinical features. A further
feature is the deposition of a limited range of proteins,
and the particular proteins involved are the basis of
the molecular pathological classification [30]. This latter
Figure 6 Western blot analysis of grey matter enriched frontal
cortex from a sCJD MM1 patient and case 2 using anti-PrP
antibodies 1E4. (a), 3F4 (b) and 94B4 (c) (epitopes as indicated on
the figure). Non-PK treated samples (−) were loaded at 6 μl/lane of
10% w/v brain homogenate, whereas PK-treated samples (+) were
loaded at the maximum of 24 μl/lane of 10% w/v brain homogenate,
but without any sample concentration pre-treatment.
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either using body fluids or substances that allow in vivo
detection of pathological protein deposition in the brain
(i.e. Pittsburgh compound B is already used for visualizingamyloid-β in Alzheimer’s disease) [31]. However, there are
numerous disease-associated protein modifications, but
their pathogenetic relevance is not yet understood fully.
The presence of PK-resistant PrP was for many years
considered the defining molecular feature of PrDs, until
CDI showed that disease-associated PrP (PrPSc) actually
exists in PK-sensitive forms in addition to the more
familiar PK-resistant forms and that PK-sensitive forms of
PrPSc usually predominate [7,32]. The significance of
senPrPSc was supported and extended by the description
of the human disease VPSPr, in which PrPSc is readily
detectable, but PrPres is found only at low and variable
levels with a highly characteristic “ladder-like” appearance
in immunoblotting [10,11].
On the basis of their clinico-pathological phenotype
we believe that the six cases reported here (1) are suffi-
ciently similar to be considered as representing examples
of the same disease entity, (2) have clinical and neuro-
pathological in common with human prion disease, (3)
fall outside the currently known spectrum of human
prion diseases, but (4) lack a plausible alternative diag-
nosis. It should be noted that in cases 5 and 6 genetic
analysis could not be performed, thus, in spite the lack
of family history for a similar disorder, we cannot ex-
clude the possibility that these cases represent atypical
forms of FFI. Furthermore, in these cases and case 3 we
could not evaluate biochemical alterations in detail and
thus we are forced to base our conclusions primarily on
the neuropathological evaluation of this group of cases
as a whole.
Biochemical aspects
One of the consistent features of the cases described
here is the presence of a highly unusual immunostaining
pattern for PrP in the cerebral cortex. The key question
that follows from this observation is, whether this novel
immunostaining pattern is accompanied by the presence
of PrP in these cases in a form that is recognised to
occur in known PrDs. Intensive investigation using the
best available methods seems to suggest that it does not.
If disease associated PrP is present in these cases it must
be i) in samples or brain regions that were not analysed
biochemically, ii) at levels below the detection limits of
Western blotting and CDI, or iii) in a form that is indis-
tinguishable from PrPC in Western blotting and CDI as
employed here. There is a growing recognition that the
analysis of highly protease-resistant PrP in the brain in
PrD does not provide a full description of the abnormal
forms of PrP present in the tissue and that protease
sensitive forms of PrP play a role in pathogenesis and
transmissibility [33]. The situation that we report here
could potentially represent a very extreme example of
this phenomenon. If true it seems to indicate that end
stage disease (i.e. in the present cases with thalamic
Figure 7 CDI analysis of the frontal cerebral cortices of the case 1, 2 and 4, and an FFI case after treatment with 0, 2.5 and 50 μg/ml
PK. (panels a, b and c, respectively). Frontal cortical brain homogenates from cases of sporadic Creutzfeldt-Jakob disease (sCJD) types MM1 and
MM2T (the latter also known as sporadic fatal insomnia, sFI) were also analysed for comparison. Note that the range of the y-axis decreases from
panel a to b to c. For case 1 and 2 duplicate frozen samples, labeled ‘a’ and ‘b’, were available for CDI analysis.
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of highly protease-resistant PrP. Whether prionopathies
that lack detectable PrPres in the brain are transmissible
(a major feature of PrDs), needs to be determined,
and transmission studies have been initiated involving
one of our cases.
Clinical features
The rapidly progressive clinical course raised the suspi-
cion of PrD in three out of the six subjects. Indeed,according to WHO Surveillance criteria [27] these cases
were classified as probable CJD, including detection of
protein 14-3-3 in the CSF. This is different from the
thalamic form of sCJD (i.e. sFI) [9]. Furthermore, there
was no evidence of a sleep disorder or autonomic dys-
function either, which would have raised this diagnosis
or would have initiated a polysomnographic examination
during life. Parkinsonism, which is also a feature of the
VPSPr cases [10], was a notable finding in some cases,
and was supported by SPECT examination of the basal
Figure 8 CDI analysis of cases compared with negative control groups. (a) Comparison of CDI values (means) for non-CJD control, sudden
death control and cerebral cortex samples. Frontal cortex samples from ten cases from the Medical Research Council Edinburgh Brain and Tissue
bank were analysed by CDI as controls. Five of these were Sudden Death cases with no history of a neurological condition (‘Sudden death’),
whereas another five were cases initially referred to NCJDRSU as suspected CJD cases, but given an alternative final diagnosis (‘non-CJD’). These
samples were analysed in comparison with three samples of cerebral cortex from cases 1 (one sample) and 2 (two samples). The upper and lower
dashed lines indicate the D-N cut-off values, these being the [mean + (2.5 X Standard Deviation)] for sudden death and non-CJD cerebral cortex
tissue, respectively. (b) Comparison of CDI values (means) for non-CJD control and sudden death control versus the individual samples from cases
1 and 2. (c) The D-N values are shown from CDI analysis of a sample of frontal cortex from cases 1 and 2 (striped bar) and sudden death cases
(black bar) or non-CJD neurological control cases (grey bars), following treatment with various concentrations of PK as indicated on the x-axis.
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compatible with the loss of neurons in the substantia
nigra and gliosis in the striatum, although the degree did
not reach that seen in Parkinson’s disease or other
neurodegenerative disease with Parkinsonism. One case
was classified as dementia with Lewy bodies on clinical
criteria and only the neuropathological evaluation clari-
fied the diagnosis. This emphasises the need for system-
atic neuropathological evaluation in the clinical setting
of rapidly progressive Parkinsonism with dementia, even
when supported by imaging findings, since dementia
with Lewy bodies may have a rapidly progressive form
also [34]. In one subject (case 2) the possibility of
Huntington’s disease was also raised, and in another
patient (case 4) hydrocephalus was observed. In the
latter, clinical examinations did not show increased
pressure and no clinical improvement was observed
after taking 30 ml CSF, but rather there was a de-
creased DAT expression in the striatum. There is a
spectrum of disorders, which may mimic PrDs [35-37]
and which were excluded both during clinical exami-
nations and neuropathology. In sum, rapid dementia is
a common feature of our cases, which show some
variability in other symptoms; concomitant patholo-
gies, which are frequent in the elderly, may influence
the symptoms [38].
Epidemiology
We note that in the period between 1993 and 2013, a
total of 249 definite CJD cases were diagnosed (spor-
adic, iatrogenic, genetic) in Austria as part of PrD
Surveillance. However, we did not observe the thal-
amic type of CJD (sFI) in this cohort. The fact that
our six cases with a similar neuropathological pheno-
type were diagnosed within two years is striking but
should be interpreted with caution; in particular the
frequency of rare diseases may vary considerably
when analysed on a yearly basis. Follow-up studies
are required to clarify these epidemiological aspects.
Interestingly, in contrast to sFI cases, which are asso-
ciated with MM at codon 129, one of the present
cases was MV. On a neuropathological level, we
could not see any major differences between this MV
case and the other cases.
Pathological diagnosis
Immunostaining for disease-associated PrP has become a
standard for the definitive diagnosis of PrDs. There are
different patterns, including synaptic, patchy/perivacuolar,
perineuronal, or plaque types, which can be detected by
an enhanced pretreatment method that includes formic
acid or PK and autoclaving [17]. Indeed, these patterns
correlate well with recognised molecular subtypes [39].
Disease-associated PrP, detectable also after PK-treatment,may also deposit intraneuronally usually associated with
the endosomal-lysosomal system but also rarely forming
inclusion bodies [21,40]. In addition, a recent study
suggested that filamentous PrP immunoreactivity may be
a common feature of genetic PrDs [41]. In the present
cases we observed none of the aforementioned immu-
nostaining patterns, but instead we observed a neuritic
distribution as a new pattern, which appeared uniformly
in each of our six cases and was not detected in our sur-
veillance cohort of various human PrDs or in a cohort of
non-PrD cases, which were processed and evaluated with
the same methods. Interestingly, only in the examined FFI
cases we detected similar cortical PrP deposits in addition
to classical synaptic type immunoreactivity. This could
support a relationship to FFI. Alternatively, it could be
theorised that damage to the thalamic neurons causes sec-
ondary damage to thalamocortical projections. Although
in 8 cases with thalamic pathology we did not observe
similar immunoreactivities, we cannot exclude this possi-
bility. Still this indicates that PrP may undergo conform-
ational change, which expands beyond the well-established
morphologies. In a single case we detected microha-
emorrhages in the hypothalamus suggestive of Wernicke-
encephalopathy. However, we did not observe signs of a
chronic form of Wernicke encephalopathy, moreover in six
cases with classical morphological features of Wernicke
encephalopathy, there was a lack of similar PrP immunore-
activity in the cortex. Interestingly, Wernicke encephalop-
athy may associate with sCJD [42]. Although reminiscent
of the recently reported filamentous PrP immunoreactivity
[41], the peculiar immunoreactivity in our cases was
confined to the 2nd and 3rd layers of the neocortex or
occasionally to the molecular layer of the cerebellum but
was never observed in the white matter. The peculiar
branching type of cortical immunoreactivity in our series
of cases was abolished by PK-treatment of sections and
somewhat increased by the omission of the formic acid
pre-treatment. Interestingly, some samples in the above
study on filamentous PrP immunoreactivity [41] also
lacked PK-resistant PrP; however it was not stated whether
samples showing the immunoreactivity were evaluated or
not [41]. The neuritic immunoreactivity in our cases was
not uniformly detectable by all of the anti-PrP antibodies
used. Thus, care must be taken which anti-PrP antibody is
used when evaluating cases with thalamic degeneration
without alternative pathologies. In our ultrastructural
analysis, we were able to examine the same section used
for light microscopy and electron microscopy [21], and
demonstrated the presence of PrP immunoreactivity
associated with endosomes, which are crucial players in
the processing of PrP [43]. The lack of detection using the
N-terminal anti-PrP antibody also suggests that PrP
undergoes processing (i.e. truncation) within the cell.
Furthermore, the unique detection of this type of PrP
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following PK treatment, supports the notion that this
neuritic PrP immunoreactivity pattern could be the
immunomorphological representative of a disease-
associated PK-sensitive PrP conformer (senPrPSc).
Thermolysin has previously been shown to digest PrPC
leaving both PK sensitive and resistant PrPSc isoforms
undigested [20]. The concept that some PrP deposits
may contain PK-sensitive PrP is further supported by
recent observations in a genetic prion disease case car-
rying a 144 base pair insertion [44]. There are further
immunostaining patterns associated with non-PrDs
that are thought to represent PrPC [45,46]. A similar
neuritic pattern has not been described; moreover, in
our cases we excluded ischaemic/hypoxic damage as a
potential cause for PrPC upregulation. Additionally,
the lack of neuritic anti-APP immunoreactivity was
not suggestive of a defect of the acute axonal trans-
port. Thus, in addition to the already characterised
immunomorphology of physiological cellular PrP [45]
and disease-associated PrP with corresponding PK-
resistance in immunoblottting [17], further comparative
studies are needed to characterise the spectrum of immu-
noreactivities that represent conformationally altered
(“disease-associated”) PrP forms with PK-sensitivity (i.e.
senPrPSc). In 2005, Safar et al. suggested that CDI is sub-
stantially more sensitive than immunohistochemistry [7].
This report places some constraints on the interpretation
of CDI in a diagnostic role and shows how immunohisto-
chemistry remains useful especially in atypical cases such
as these.
Conclusion
In conclusion, we present here six cases with a
uniform neuropathological phenotype (thalamic degen-
eration with cortical neuritic PrP immunoreactivity)
associated with a fatal clinical disease and rapidly pro-
gressive dementia and (where tested) with apparently
PK-sensitive disease-associated PrP. The neuropatho-
logical phenotype shows similarities with sporadic and
familial fatal insomnia. In the present study we cannot
conclude whether the observed biochemical phenotype
is related to the spectrum of atypical prionopathies or
reflects a completely different disease-process. Whether
the present cases represent a PK-sensitive subtype of
sporadic fatal insomnia (also called MM type 2-thal-
amic) or a different entity, possibly even unrelated to
the PrDs, merits further study. Clinico-pathological
aspects of these cases have implications for the dif-
ferential diagnosis and pathogenesis of neurodegene-
rative diseases, as well as for surveillance of human
prion diseases. Neurodegeneration may be present in
the brain without prominent pathological protein
depositions.Additional file
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